Arkolith/Insider Trading/GTBP/Form 4

Breen Michael Martin

Exec. Chair. and Interim CEO, DirectorGT Biopharma, Inc. (GTBP) · full profile →Form 4 · filed Jul 19, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 15, 2022Grant(A)278K—$0606K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 15, 2022Grant(A)50K—$050K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-22-019876) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML